Deadline: 23-Aug-2025
The Indian Council of Medical Research (ICMR), New Delhi is inviting Expressions of Interest (EoI) from eligible organizations, companies, and manufacturers for the transfer of technology related to a “Plant Extract Based Composition Useful for Leishmania Promastigote.” This composition is effective for Leishmania promastigote culture drug sensitivity testing and is intended for commercialization.
The objective is to license the technology for marketing and production purposes. ICMR is looking to collaborate with interested entities to facilitate the transfer of this technology. Selected companies will be granted rights to develop, manufacture, and commercialize the product. The licensing agreement will be non-exclusive and may involve one or more companies to ensure wide accessibility for public health benefits. All agreements will follow ICMR’s Intellectual Property (IP) Policy.
The Rajendra Memorial Research Institute of Medical Sciences (RMRIMS), under ICMR, holds the expertise and technical knowledge for this technology. They will provide technical support and guidance throughout the production and commercialization process. ICMR’s scientific team will offer assistance in study planning, data analysis, protocol development, and safety and efficacy assessments, depending on mutual agreement with the chosen partner.
ICMR will also support R&D or clinical studies through its affiliated institutes and will assist in validation of the product, as required. However, ICMR will not bear any financial responsibility unless explicitly agreed upon in the contract.
To qualify, applicants must be legally registered in India with majority Indian ownership. They must be compliant with tax and administrative authorities and have a track record of manufacturing or R&D experience over the last three years. Applicants should have marketed similar products previously and maintain financial profitability without incurring losses in the past three years. They must not be blacklisted by any government body and must have an Indian manufacturing facility. Additionally, their promoters must not have any convictions within the last three years.
Applicants must also possess GMP or equivalent quality certifications and GLP or relevant certifications for R&D. They should have a functioning laboratory for R&D and adequate capacity to produce the composition in significant quantities each week.
Proposals will be rejected if they are incomplete, improperly formatted, unstamped, unsigned, late, or missing supporting documents. Any proposal that deviates materially from the specified requirements or does not comply with the terms of the EoI will also be disqualified.
For more information, visit ICMR.
